In our screening, the compound 3F1 was considered a hit-to-lead compound as the respective IC50 dose against breast cancer cells such as MDA-MB-231 (8.435 μM ± 0.809), MCF-7 (6.174 μM ± 0.660), BCA (5.770 μM ± 0.907), and BCSC-P (4.522 μM ± 0.537) was less than 10 μM, though this was not observed for BCSC, which showed an IC50 of 10.170 μM ± 0.417. Here, BLNK is linked to breast carcinoma.